When the intravenous single-molecule administrations of arbitrary ADCs are conducted, the trajectories to the target cancer tissue based on the systemic circulation and the EPR effect are different in each trial, dependent on the presence or absence of salvation by the FcRn, the interaction with plasma proteins and immune cells, and other factors such as which blood vessels are passed through, which cells are interacted with, and which leaky gap they fall into based on the EPR effect. This evidence concerns the gene FCGRT and cancer.